Vanessa Research

Vanessa Biotech (VB) is a biomedical company founded on the desire to "give hope where none existed" by making an impact on healthcare markets often overlooked. Its continually expanding pipeline of innovative pharmaceuticals, medical devices and consumer and public health products reflects the company's inventive nature and commitment to delivering solutions that increase access to quality care. The company's flagship product, Shylicine™, is the first-ever drug developed to treat the rare and lethal microvillus inclusion disease. Vanessa Biotech, a University of Connecticut Technology Incubation Program participant, has global offices in Hungary, Spain, and Germany in addition to its Hamden, Conn. corporate campus.